[PDF][PDF] mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 omicron variant

VV Edara, KE Manning, M Ellis, L Lai, KM Moore… - Cell Reports …, 2022 - cell.com
VV Edara, KE Manning, M Ellis, L Lai, KM Moore, SL Foster, K Floyd, ME Davis-Gardner…
Cell Reports Medicine, 2022cell.com
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) omicron variant
emerged in November 2021 and consists of several mutations within the spike. We use
serum from mRNA-vaccinated individuals to measure neutralization activity against omicron
in a live-virus assay. At 2–4 weeks after a primary series of vaccinations, we observe a 30-
fold reduction in neutralizing activity against omicron. Six months after the initial two-vaccine
doses, sera from naive vaccinated subjects show no neutralizing activity against omicron. In …
Summary
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) omicron variant emerged in November 2021 and consists of several mutations within the spike. We use serum from mRNA-vaccinated individuals to measure neutralization activity against omicron in a live-virus assay. At 2–4 weeks after a primary series of vaccinations, we observe a 30-fold reduction in neutralizing activity against omicron. Six months after the initial two-vaccine doses, sera from naive vaccinated subjects show no neutralizing activity against omicron. In contrast, COVID-19-recovered individuals 6 months after receiving the primary series of vaccinations show a 22-fold reduction, with the majority of the subjects retaining neutralizing antibody responses. In naive individuals following a booster shot (third dose), we observe a 14-fold reduction in neutralizing activity against omicron, and over 90% of subjects show neutralizing activity. These findings show that a third dose is required to provide robust neutralizing antibody responses against the omicron variant.
cell.com